(Q43848133)

English

Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

scientific article published in November 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 November 2017

Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer (English)

1 reference

Europe PubMed Central

27 November 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

27 November 2017

author name string

Morgan RJ

1

1 reference

Europe PubMed Central

27 November 2017

Doroshow JH

2

1 reference

Europe PubMed Central

27 November 2017

Leong L

3

1 reference

Europe PubMed Central

27 November 2017

Schriber J

4

1 reference

Europe PubMed Central

27 November 2017

Shibata S

5

1 reference

Europe PubMed Central

27 November 2017

Forman S

6

1 reference

Europe PubMed Central

27 November 2017

Hamasaki V

7

1 reference

Europe PubMed Central

27 November 2017

Margolin K

8

1 reference

Europe PubMed Central

27 November 2017

Somlo G

9

1 reference

Europe PubMed Central

27 November 2017

Alvarnas J

10

1 reference

Europe PubMed Central

27 November 2017

McNamara M

11

1 reference

Europe PubMed Central

27 November 2017

Raschko J

13

1 reference

Europe PubMed Central

27 November 2017

Chow W

14

1 reference

Europe PubMed Central

27 November 2017

Vasilev S

15

1 reference

Europe PubMed Central

27 November 2017

McGonigle K

16

1 reference

Europe PubMed Central

27 November 2017

Yen Y

17

1 reference

Europe PubMed Central

27 November 2017

language of work or name

0 references

publication date

1 November 2001

1 reference

Europe PubMed Central

27 November 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

27 November 2017

28

1 reference

Europe PubMed Central

27 November 2017

859-863

1 reference

Europe PubMed Central

27 November 2017

9

1 reference

Europe PubMed Central

27 November 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703243

0 references

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

21 January 2018

Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

21 January 2018

Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

21 January 2018

Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

21 January 2018

High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

21 January 2018

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

21 January 2018

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

21 January 2018

Impact of doxorubicin on survival in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

21 January 2018

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

21 January 2018

The role of chemotherapy in the management of celomic epithelial carcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

21 January 2018

High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma: long term results for 105 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

21 January 2018

Therapy of ovarian carcinoma: The relationship of dose level and treatment intensity to survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

21 January 2018

High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer of the ovary

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose intensity analysis of chemotherapy regimens in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703243

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1703243

1 reference

Europe PubMed Central

27 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

27 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43848133&oldid=2103854348"